# OnCo record nrg-gy018-keynote-868 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nrg-gy018-keynote-868/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nrg-gy018-keynote-868", "NCT03914612" ;
  schema:name "NRG-GY018 / KEYNOTE-868"@en ;
  schema:description "NRG-GY018 is the pembrolizumab twin of RUBY: immunotherapy plus chemotherapy cut the risk of progression by 70% in dMMR tumours and 46% in the rest."@en ;
  schema:url <https://onco.cc/trials/nrg-gy018-keynote-868/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03914612>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2302312> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2019-08-22" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>, <https://onco.cc/cancers/endometrial-nsmp/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/nrg-oncology/>, <https://onco.cc/companies/gog-foundation/> ;
  onco:terms <https://onco.cc/terms/msi/> ;
  onco:people <https://onco.cc/people/ramez-eskander/> .